放疗对乳腺管状癌预后的影响
基于美国国家癌症数据库2004—2015年9705例pN0M0管状癌保乳术后患者,75.1%接受放疗。倾向评分匹配后,放疗与内分泌治疗为总生存有利预后因素,放疗组5年及10年总生存均优于未放疗组。
要点
- pN0M0管状癌保乳术后放疗与更好总生存相关。
- 匹配后放疗组5年总生存91.7% vs 84.5%,10年76.1% vs 64.1%。
- 年龄>60岁、黑人种族及合并症评分>0为不利预后因素。
核心结论
- pN0M0管状癌保乳术后辅助放疗是总生存的有利预后因素,提示应维持为标准治疗。
研究设计与样本
- 回顾性查询美国国家癌症数据库2004—2015年pN0M0管状癌保乳术后患者,共9705例纳入分析。
主要发现
- 9705例中6182例(75.1%)接受放疗,2045例(24.9%)未接受放疗。
- 倾向评分匹配后多因素Cox分析显示放疗(HR 0.582;95%CI 0.494-0.686)和内分泌治疗(HR 0.737;95%CI 0.623-0.872)为有利预后因素。
- 年龄>60岁(HR 5.131;95%CI 3.753-7.016)、黑人种族(HR 1.445;95%CI 1.016-2.055)、Charlson-Deyo合并症评分>0(HR 1.708;95%CI 1.403-2.079)为不利预后因素。
- 匹配后放疗组与未放疗组5年总生存分别为91.7%和84.5%,10年总生存分别为76.1%和64.1%(p<0.001)。
临床怎么用
- 对pN0M0管状癌保乳术后患者,辅助放疗可作为标准治疗推荐以改善总生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Tubular carcinoma (TC) is an invasive breast cancer with favorable prognosis. While pathology-specific guidelines exist for TC regarding adjuvant chemotherapy and endocrine therapy, no recommendations exist regarding locoregional treatment based on tumor histology. Prognostic impact of radiotherapy for patients with TC remains unclear. MATERIALS AND METHODS: The National Cancer Database was queried (2004-2015) for patients with pN0M0 TC who underwent lumpectomy. Chi-square testing compared categorized variables between those who did and did not receive radiotherapy. Kaplan-Meier analysis evaluated overall survival (OS). Cox proportional hazard analysis identified variables prognostic for OS. Patients were divided into age cohorts ≤60 years and >60 years. Propensity score matching (PSM) was utilized to create similar cohorts. RESULTS: 9705 patients met selection criteria; 6182 (75.1%) received radiotherapy while 2045 (24.9%) did not. After PSM, radiotherapy (HR 0.582; 95% CI 0.494-0.686) and endocrine therapy (HR 0.737; 95% CI 0.623-0.872) were favorable prognostic factors on multivariate Cox regression analysis while age > 60 years (HR 5.131; 95% CI 3.753-7.016), Black race (HR 1.445; 95% CI 1.016-2.055), and Charlson-Deyo comorbidity score > 0 (HR 1.708; 95% CI 1.403-2.079) were unfavorable prognostic factors. After PSM, 5-year OS was 91.7% for those who received radiotherapy and 84.5% for those who did not; 10-year OS was 76.1% and 64.1%, respectively (p < 0.001). CONCLUSION: This is the largest study to date on TC and the prognostic impact of adjuvant radiotherapy. Postoperative radiotherapy is a favorable prognostic factor for OS in patients with pN0M0 TC, suggesting adjuvant radiotherapy should remain standard of care in these patients.
引用
- Stauber J, Chevli N, Haque W, et al. Prognostic impact of radiation therapy in tubular carcinoma of the breast. Radiother Oncol. 2021. PMID: 33753158. doi:10.1016/j.radonc.2021.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。